formic acid-[4-(6-methyl-benzothiazol-2-yl)-anilide] | 95856-69-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: formic acid-[4-(6-methyl-benzothiazol-2-yl)-anilide]
• 英文别名: Ameisensaeure-[4-(6-methyl-benzothiazol-2-yl)-anilid]；4-(6-Methyl-1,3-benzothiazol-2-yl)phenylformamide；N-[4-(6-methyl-1,3-benzothiazol-2-yl)phenyl]formamide
• CAS: 95856-69-2
• 化学式: C₁₅H₁₂N₂OS
• 分子量: 268.339
• InChiKey: FOXZRHHATWWOQJ-UHFFFAOYSA-N

物化性质

• 沸点：
  501.4±52.0 °C(Predicted)
• 密度：
  1.311±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  70.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  甲酸 、 2-(4-氨基苯基)-6-甲基苯并噻唑 生成 formic acid-[4-(6-methyl-benzothiazol-2-yl)-anilide]
  参考文献：
  名称：

  Weisswange,W., Diss 33

  摘要：

  DOI：

文献信息

• Weisswange,W., Diss <Halle 1925> 33
  作者：Weisswange,W.

  DOI：——

  日期：——
• TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF
  申请人：LION Bioscience AG

  公开号：EP1189891A1

  公开（公告）日：2002-03-27
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Genzyme Corporation

  公开号：US20180093981A1

  公开（公告）日：2018-04-05

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
• US6362342B1
  申请人：——

  公开号：US6362342B1

  公开（公告）日：2002-03-26
• US9744153B2
  申请人：——

  公开号：US9744153B2

  公开（公告）日：2017-08-29